Filing Flows › Comparisons › PEN vs HAE
Penumbra vs Haemonetics: PEN and HAE compared
Penumbra is the larger company: $410M of revenue in its latest quarter (Q3 2026) against $358M for Haemonetics (Q2 FY27). Penumbra is growing faster (+16% against +9% a year earlier). Haemonetics is more profitable, with an operating margin of 21.0% against 12.4%.
Where the money goes: PEN and HAE
Penumbra (PEN) · Q3 2026
Penumbra, Q3 2026: revenue $410M (+16% year over year), operating margin 12.4%, net earnings $42.3M, operating cash flow $41.5M. The chart follows the revenue to costs, profit and cash.
Haemonetics (HAE) · Q2 FY27
Haemonetics, Q2 FY27: revenue $358M (+9% year over year), operating margin 21.0%, net earnings $46.3M, operating cash flow $128M. The chart follows the revenue to costs, profit and cash.
| Penumbra (PEN) | Haemonetics (HAE) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 FY27 |
| Revenue | $410M | $358M |
| Revenue growth, Y/Y | +16% | +9% |
| Gross margin | 68.3% | 61.7% |
| Operating margin | 12.4% | 21.0% |
| Net earnings | $42.3M | $46.3M |
| Net margin | 10.3% | 12.9% |
| Operating cash flow | $41.5M | $128M |
| Free cash flow | $26.4M | $113M |
| Market value | $12.6B | $5.6B |
| P/E | 80.4× | 53.6× |
| Analysts’ mean target | $362.54 | $124.50 |
Where the revenue comes from
Penumbra
- Thrombectomy: $279M (68%)
- Embolization and Access: $131M (32%)
Haemonetics
- Apheresis: $205M (57%)
- MedSurg: $153M (43%)
Questions
Which is bigger, Penumbra or Haemonetics?
Penumbra is the larger company: $410M of revenue in its latest quarter (Q3 2026) against $358M for Haemonetics (Q2 FY27).
Is Penumbra or Haemonetics growing faster?
Penumbra is growing faster (+16% against +9% a year earlier).
Which is more profitable, Penumbra or Haemonetics?
Haemonetics is more profitable, with an operating margin of 21.0% against 12.4%.
More: Penumbra earnings · how Penumbra makes money · Haemonetics earnings · how Haemonetics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.